Read by QxMD icon Read

Hepatology International

Tatsuo Kanda, Shunichi Matsuoka, Mitsuhiko Moriyama
No abstract text is available yet for this article.
July 10, 2018: Hepatology International
Danqing Hu, Hongwu Wang, Hai Wang, Yaqi Wang, Xiaoyang Wan, Weiming Yan, Xiaoping Luo, Qin Ning
OBJECTIVE: The relationship between chronic hepatitis B virus (HBV) infection and fatty liver in patients remains unclear. Although high-fat diets-induced hepatic steatosis was proved to reduce HBV replication in transgenic mice, the interplay between HBV and fatty liver in immunocompetent mouse model is yet to be elucidated. Here, we aimed to develop an effective animal model for intracellular HBV persistence combined with hepatic steatosis and to explore their interactions. METHODS: FVB/N mice with HBV genotype B replicon DNA were established by hydrodynamic injection...
July 5, 2018: Hepatology International
Akash Shukla, Pratin Bhatt, Deepak Kumar Gupta, Tejas Modi, Jatin Patel, Amit Gupte, Megha Meshram, Shobna Bhatia
There are limited data on clinical profile of adolescent patients with Budd-Chiari syndrome (BCS). We studied clinical, radiological, thrombophilia profile and treatment outcomes in adolescent patients with BCS. METHODS: Forty-three consecutive patients of BCS with onset of symptoms during adolescence (10-19 years) were enrolled in the study. 129 randomly selected adult patients with BCS and 36 children with BCS formed the two control groups. The clinical history, physical examination, laboratory tests, thrombophilic disorders, radiological features and treatment outcomes of adolescents were compared to adults and children...
July 3, 2018: Hepatology International
Seogsong Jeong, Guijuan Luo, Zhi-Heng Wang, Meng Sha, Lei Chen, Qiang Xia
BACKGROUND AND AIMS: To estimate the impact of viral hepatitis B status on outcomes of intrahepatic cholangiocarcinoma. METHODS: We searched Pubmed and Embase for original articles that evaluated the impact of hepatitis B virus infection on outcomes of intrahepatic cholangiocarcinoma. The present study was conducted to generate odd ratios (ORs) with 95% confidence intervals (CIs) for pre-identified prognostic factors, overall survival, and recurrence. RESULTS: From 438 studies, we identified eight articles that compared outcomes between hepatitis B virus-infected patients and the others...
June 26, 2018: Hepatology International
Sern Wei Yeoh, Alex C N Holmes, Michael M Saling, Ian P Everall, Amanda J Nicoll
Patients with chronic hepatitis C virus (HCV) infection experience a range of symptoms including depression, fatigue and neurocognitive deficits, impairing quality of life. Depression, in particular, may be reactive to increased psychosocial stress, and the physical symptoms of advanced HCV or associated comorbidities. However, even patients at an early stage of HCV infection, with minimal hepatic inflammation or comorbidities, report more depressive symptoms and fatigue than the general population. Similarly, specific neurocognitive deficits occur in early stage HCV infection and are independent of the presence of depression or encephalopathy...
June 21, 2018: Hepatology International
Rahima A Bhanji, Carlos Moctezuma-Velazquez, Andres Duarte-Rojo, Maryam Ebadi, Sunita Ghosh, Christopher Rose, Aldo J Montano-Loza
BACKGROUND: Skeletal muscle is known to play a role in hepatic encephalopathy. Fatty infiltration of the muscle (myosteatosis) and muscle mass depletion (sarcopenia) are frequent complications of cirrhosis. PURPOSE: The purposes of the study were to investigate if myosteatosis and sarcopenia are associated with overt hepatic encephalopathy in patients with cirrhosis and to evaluate their impact on mortality. METHODS: A total of 675 cirrhotic patients were studied...
June 7, 2018: Hepatology International
Jin-Lin Cheng, Hong Zhao, Shi-Gui Yang, Er-Mei Chen, Wen-Qian Chen, Lan-Juan Li
BACKGROUND: Plasma microRNA (miRNA) levels may be altered during pathological processes; therefore, they may potentially serve as biomarkers for the diagnosis and prognosis of human diseases. This study aimed to explore whether plasma miRNAs may serve as new biomarkers for liver injury among chronic hepatitis B (CHB) patients with normal or nearly normal alanine aminotransferase (ALT) levels. METHODS: Plasma miRNAs from each of three independent groups (no prominent liver injury and persistently normal ALT levels, NPNALT; significant liver injury with persistently normal ALT levels, SPNALT; and healthy) were profiled by miRNA microarray analysis...
June 7, 2018: Hepatology International
Masashi Kudo, Naoto Gotohda, Motokazu Sugimoto, Tatsushi Kobayashi, Motohiro Kojima, Shinichiro Takahashi, Masaru Konishi, Ryuichi Hayashi
BACKGROUND: Magnetic resonance imaging with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (EOB-MRI) is a diagnostic modality for liver tumors. Three-dimensional (3D) volumetric analysis systems using EOB-MRI data are used to simulate liver anatomy for surgery. This study was conducted to investigate clinical utility of a 3D volumetric analysis system on EOB-MRI to evaluate liver function. METHODS: Between August 2014 and December 2015, 181 patients underwent laboratory and radiological exams as standardized preoperative evaluation for liver surgery...
June 2, 2018: Hepatology International
(no author information available yet)
The aim of this erratum is to correct the sequence of the authors which were listed erroneously in the published version. The correct sequence is mentioned below.
May 23, 2018: Hepatology International
Adel Abdel-Moneim, Alaa Aboud, Mohamed Abdel-Gabaar, Mohamed I Zanaty, Mohamed Ramadan
BACKGROUND AND AIM: Clinical studies evaluating the efficacy of daclatasvir (DCV) for treatment of chronic hepatitis C virus (HCV) genotype 4 (GT4) infection are scarce. This study aims to evaluate the efficacy and safety of DCV plus sofosbuvir (SOF) with or without ribavirin (RBV) for treatment of Egyptian patients infected with HCV GT4. METHODS: Between April 2016 and March of 2017, a large cohort of 946 patients with chronic HCV GT4 was enrolled for completing the treatment...
May 12, 2018: Hepatology International
Antonio Riva, Shilpa Chokshi
Alcoholic liver disease (ALD) is an escalating global problem accounting for more than 3 million deaths annually. Bacterial infections are diagnosed in 25-47% of hospitalized patients with cirrhosis and represent the most important trigger for acute decompensation, multi-organ failure, septic shock and death. Current guidelines recommend intensive antibiotic therapy, but this has led to the emergence of multi-drug resistant bacteria, which are associated with increased morbidity and mortality rates. As such, there is a pressing need to explore new paradigms for anti-infective therapy and host-directed immunomodulatory therapies are a promising approach...
May 8, 2018: Hepatology International
Martin C S Wong, Junjie Huang
No abstract text is available yet for this article.
April 20, 2018: Hepatology International
Tianyu He, Yuqing Bai, Haodong Cai, Xiaojuan Ou, Min Liu, Wei Yi, Jidong Jia
The aim of this erratum is to clearly state the individual author's contribution which was erroneously mentioned as "Tianyu He, Yuqing Bai, Wei Yi, and Jidong Jia contributed equally to this work."
May 2018: Hepatology International
Fumitaka Suzuki, Naoya Hatanaka, Etsuya Bando, Koji Nakamura, Akira Komoto
BACKGROUND: Safety and effectiveness of daclatasvir (DCV)/asunaprevir (ASV) dual therapy were demonstrated in Japanese patients with chronic hepatitis C (CHC) genotype (GT) 1b in phase III studies. This postmarketing surveillance (PMS) was conducted to assess the safety and effectiveness of DCV/ASV in Japanese patients with GT-1 CHC treated in routine clinical practice. METHODS: This PMS was conducted between September 2014 and February 2017 at 261 centers in Japan...
May 2018: Hepatology International
William Bernal, Roger Williams
The King's prognostic criteria for patients with acute liver failure (ALF) introduced in 1989 have been used worldwide. This distinguished for the first time cases with 'hyper-acute' course (characteristically paracetamol overdose) where there is a better chance of recovery with medical supportive care alone from those etiologies with a less acute course and paradoxically lower chances of 'spontaneous' recovery. Ongoing use showed the limited sensitivity of the criteria to constitute a significant practical limitation...
May 2018: Hepatology International
Ameer Abutaleb, Shyam Kottilil, Eleanor Wilson
Hepatitis C virus (HCV) treatments have dramatically progressed from poorly tolerated, moderately successful interferon-based therapies to highly effective all-oral interferon-free regimens. While sustained virologic responses have significantly improved with fixed-dose combinations (FDC) of these direct-acting antivirals (DAA), cost remains high and certain populations of patients remain difficult to treat. Glecaprevir (GLE, an NS3/4A protease inhibitor) and pibrentasvir (PIB, NS5A inhibitor) were recently approved as a FDC therapy for HCV, and have expanded reach, reduced cost, and in certain populations, reduced HCV treatment duration...
May 2018: Hepatology International
Nan Chen, Xiaohong Chen, Xiaoqiang Ding, Jie Teng
BACKGROUND: To investigate the incidence, risk, and prognostic factors of acute kidney injury (AKI) in acute-on-chronic liver failure (ACLF) patients. METHODS: A total of 188 patients were prospectively included and divided into AKI and non-AKI groups. Patients were followed at 1, 3, 7, 14, 28, 60, and 90 days after the onset of AKI. Significant risk factors were screened by univariate and Cox multivariate survival analyses to confirm the independent risk factors for 30- or 90-day mortality and the 90-day renal function recovery rate...
May 2018: Hepatology International
Lin Wang, Bingqiong Wang, Hong You, Xiaoning Wu, Jialing Zhou, Xiaojuan Ou, Jidong Jia
BACKGROUND AND AIM: Reduction of platelet count is often observed in chronic hepatitis B (CHB) patients with significant liver fibrosis. In this cohort study, we investigated whether platelets' increase after entecavir (ETV) therapy was associated with the improvement of liver fibrosis. METHODS: We collected the data of a cohort 82 CHB patients with paired liver biopsies before and after 78-week ETV therapy, and assessed the platelets' change following the treatment and further investigated the associated clinical factors with platelets' change...
May 2018: Hepatology International
Wankyo Chung, Changik Jo, Woo Jin Chung, Dong Joon Kim
BACKGROUND: Liver cirrhosis is known to have low survival rate, and its assessment in relation with other fatal diseases will help us design appropriate health interventions. This study compares the mortality of liver cirrhosis with that of five major cancers (lung, colorectal, stomach, liver, and breast cancers). METHODS AND RESULTS: We used the National Health Insurance Service-National Sample Cohort (NHIS-NSC) which provides data for 1,025,340 representative samples of the 46,605,433 people in Korea from 2002 to 2010...
May 2018: Hepatology International
G Shiha, R Soliman, M ElBasiony, A A Hassan, N N H Mikhail
INTRODUCTION: New regimens involving direct-acting antiviral agents have recently been approved for the treatment of HCV. Our aim was to assess the efficacy and safety of 12 or 24 weeks of Sofosbuvir 400 mg plus Daclatasvir 60 mg, with or without ribavirin (800-1000 mg) in treating chronic hepatitis C genotype 4 patients. METHODS: This is an open-label observational study that describes the effect of 12 week or 24 weeks of daily oral Sofosbuvir (SOF) 400 mg plus Daclatasvir (DCV) 60 mg with or without ribavirin (RBV) with dose adjustment if indicated...
April 16, 2018: Hepatology International
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"